ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparative Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Composite Surrogate Markers of Insulin Resistance: A Real-World Study Using METS-IR and SPISE.Journal of clinical medicine · 2026Article
- Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Polish healthcare professionals' perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland.Frontiers in endocrinology · 2026Article
- Clinical Outcomes Associated with the Use of a Family-Based Digital Support Program in Patients with Pharmacologic Treatment for Obesity.Journal of clinical medicine · 2025Article
- Comment on: "Relative Effectiveness and Safety of the GLP-1 Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics" [Letter].Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes. Patients and Methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18-80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2). Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.